Cannabis rescheduling is not final. The DEA has proposed moving cannabis from Schedule I to Schedule III, following a 2023 recommendation from HHS. The most reliable source for updates is the DEA's Federal Register docket, because it is the primary document, it shows the official timeline, and it spells out what changes for hemp and CBD. The criteria for a good update source are authority, timeline clarity, and direct impact on legal hemp products.

latest news on cannabis rescheduling

What "rescheduling" means

Rescheduling changes a drug's placement in the Controlled Substances Act. Cannabis sits in Schedule I, which is for drugs with no accepted medical use and a high potential for abuse. Schedule III is for drugs with a moderate to low potential for physical and psychological dependence. Moving cannabis to Schedule III would not make it legal like alcohol. It would recognize medical use under federal law and allow more research and tax deductions for state-legal businesses.

cannabis rescheduling latest updates

  • Schedule I: No federal medical recognition. Strict research barriers.
  • Schedule III: Federal medical recognition. Lower abuse potential category.

Timeline of latest updates

  1. August 2023: HHS recommends rescheduling cannabis to Schedule III.
  2. May 2024: DEA issues a proposed rule to reschedule cannabis to Schedule III.
  3. July 2024: Public comment period closes.
  4. Next step: DEA final rule, which may face legal challenges.

These steps are administrative. They do not change state laws. They also do not change the legal status of hemp-derived CBD, which was legalized by the 2018 Farm Bill.

read more

Pros and cons of Schedule III for the CBD market

Pros

  • Reduces federal ambiguity for cannabis-related businesses.
  • Supports more clinical research on cannabinoids.
  • May improve banking and tax treatment for state-legal operators.

Cons

  • Does not legalize recreational cannabis at the federal level.
  • Could create new FDA rules for cannabis products, including CBD.
  • Leaves state-by-state patchwork in place.

Use-case recommendation: For a CBD store or consumer, rescheduling is a signal to watch, not a reason to change product labels or marketing claims. Hemp-derived CBD remains legal under federal law when it follows Farm Bill rules.

current status of cannabis rescheduling

What it means for CBD and hemp

Rescheduling cannabis does not reschedule hemp. Hemp is defined by law as cannabis with less than 0.3% THC on a dry weight basis. That definition stays the same unless Congress changes it. A Schedule III cannabis category could still affect CBD if the FDA decides to treat cannabis-derived CBD as a controlled substance, but that outcome is not automatic. The FDA has said it wants a new regulatory pathway for CBD products. Rescheduling may prompt that pathway, but it is a separate process.

How to follow updates

  1. Check the Federal Register for the DEA's proposed and final rules.
  2. Read DEA press releases and the Department of Justice website.
  3. Track bills in Congress that amend the Controlled Substances Act.
  4. Follow state cannabis regulators for local changes.

Use primary sources. A proposed rule is not a final rule. A final rule can take effect after a waiting period. Legal challenges can delay or block a final rule. For now, cannabis remains Schedule I under federal law. Hemp-derived CBD remains legal under the Farm Bill. Any change to rescheduling will take time to reach the market.